Floatz logo

Pembrolizumab

Oropharynx Cancer

Turnstone Biologics, Corp.monoclonal_antibodyPhase 2Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

3 Active assets in the Oropharynx Cancer cohort.

Asset / SponsorPhaseRating
e7 tcr-t cells
Christian Hinrichs
Phase 2B
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2CCC
BENZOIC ACID, 4-((4-AMINO-3-(4-CYCLOHEXYL-1-PIPERAZINYL)-9,10-DIHYDRO-9,10-DIOXO-1-ANTHRACENYL)AMINO)-
VM Oncology, LLC
Phase 1/2CCC
Tbio-6517
Turnstone Biologics, Corp.
Phase 1CC

Same molecule, other indications

Pembrolizumab is also rated in:

Her2-receptor negative breast cancerDormant
BBB
Indicative ·
72 / 100
View asset →
estrogen-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →
progesterone-receptor negative breast cancerDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →